Abeona Therapeutics Inc./$ABEO
1D1W1MYTD1Y5YMAX
Capital at risk
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
- Ticker
- $ABEO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 226
- Headquarters
- Cleveland, United States
- Website
- www.abeonatherapeutics.com
ABEO Metrics
BasicAdvanced
$307M
-
-$1.18
1.34
-
Price and volume
Market cap
$307M
Beta
1.34
52-week high
$7.65
52-week low
$4.00
Average daily volume
1.5M
Financial strength
Current ratio
6.635
Quick ratio
6.318
Long term debt to equity
0.041
Total debt to equity
0.155
Interest coverage (TTM)
-25.25%
Profitability
EBITDA (TTM)
-80.789
Gross margin (TTM)
-39.90%
Net profit margin (TTM)
-246.42%
Operating margin (TTM)
-327.64%
Effective tax rate (TTM)
19.68%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-24.55%
Return on equity (TTM)
-43.13%
Valuation
Price to revenue (TTM)
11.74
Price to book
2.4
Price to tangible book (TTM)
2.4
Price to free cash flow (TTM)
-3.675
Free cash flow yield (TTM)
-27.21%
Free cash flow per share (TTM)
-1.461
Growth
Revenue change (TTM)
6,280.00%
Earnings per share change (TTM)
-219.53%
3-year revenue growth (CAGR)
92.67%
10-year revenue growth (CAGR)
38.98%
3-year earnings per share growth (CAGR)
-25.62%
10-year earnings per share growth (CAGR)
-22.86%
Bulls say / Bears say
ZEVASKYN adoption is showing early commercial momentum: Q2 net revenue increased 31% sequentially to $11.4 million, five patients were treated during the quarter, and three additional treatments had been completed in Q3 to date as of August 13, 2026. (Abeona Therapeutics Q2 2026 8-K)
The treatment-center and reimbursement infrastructure is expanding: the qualified treatment-center network reached seven sites, while CMS granted ZEVASKYN New Technology Add-On Payment status effective October 1, 2026, potentially supporting hospital adoption for eligible Medicare patients. (Abeona Therapeutics Q2 2026 8-K)
Abeona had $146.8 million in cash, cash equivalents and short-term investments at June 30, 2026, providing meaningful funding to support the commercial rollout and advance its pipeline without an immediate need to rely solely on equity financing. (Abeona Therapeutics Q2 2026 8-K)
ZEVASKYN manufacturing execution remains a material risk: in Q2, five patients were treated but revenue was recognized for only four because one batch yielded too few sheets, while two launch patients generated no revenue because of low yield or failed lot-release specifications. (Abeona Therapeutics Q2 2026 8-K)
The company remains deeply loss-making despite commercialization: Q2 2026 net loss was $20.2 million, and cash, cash equivalents and short-term investments fell to $146.8 million from $191.4 million at December 31, 2025. (Abeona Therapeutics Q2 2026 8-K)
ABEO remains heavily dependent on ZEVASKYN because its next major development program, ABO-701, is not expected to enter first-in-human studies until the second half of 2027, while its in-house ophthalmology programs have been deprioritized. (Abeona Therapeutics Q1 2026 8-K)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Upcoming events
No upcoming events
ABEO News
AllArticlesVideos
Funds containing ABEO
Fund name | Fund size | $ABEO weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.